Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10738130
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
granted -
US 10738275
Paenibacillus sp. strain, cultivation method and use of the same
granted -
US 10738361
Methods of predicting clinical course and treating multiple sclerosis
granted -
US 10738313
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10736857
Treatment of pervasive developmental disorders with redox-active therapeutics
granted -
US 10736875
Methods and compositions associated with the granulocyte colony-stimulating factor receptor
granted -
US 10736919
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 10736975
Infusion administration of conjugated monoclonal antibodies
granted -
US 10737113
Human antibodies to PD-1
granted -
US 10738035
Hepatitis B antiviral agents
granted -
US 10738043
GLS1 inhibitors for treating disease
granted -
US 10738112
Anti-human interleukin-17A monoclonal antibody
granted -
US 10738113
Anti-IL-2 antibodies and compositions and uses thereof
granted -
US 10738123
Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
granted -
US 10738305
Materials and methods for treatment of hemoglobinopathies
granted -
US 10738312
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10736864
Immunotherapeutic agent
granted -
US 10736859
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
granted -
US 10736961
Method of averting opioid addiction
granted -
US 10736969
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
granted -
US 10736894
Methods of treating developmental syndromes with PDE10A inhibitors
granted -
US 10736915
Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
granted -
US 10736964
Immunomagnetic nanocapsule and kit for treating cancer
granted -
US 10736989
Methods and compositions for stabilizing the myocardium
granted -
US 10738004
Cyclic compound
granted -
US 10736976
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
granted -
US 10737995
Nuclear receptor modulators and their use for the treatment and prevention of cancer
granted -
US 10738017
Substituted triazoles and methods relating thereto
granted -
US 10738030
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 10738027
Crystalline forms of C21H22Cl2N4O2
granted -
US 10736880
Therapeutics for preterm labor management
granted -
US 10738009
Pyridone amides as modulators of sodium channels
granted -
US 10738010
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
granted -
US 10738014
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
granted -
US 10738036
Deuterated CFTR modulators
granted -
US 10738046
Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
granted -
US 10738047
Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
granted -
US 10738093
Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
granted -
US 10738081
Peptide with anti-obesity and anti-diabetes activity and use thereof
granted -
US 10745474
Methods of treating inflammation associated airway diseases and viral infections
granted -
US 10745475
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
granted -
US 10745680
Factor IX fusion proteins and methods of making and using same
granted -
US 10745481
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
granted -
US 10745665
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
granted -
US 10745702
Compositions and methods for inhibiting expression of the LECT2 gene
granted -
US 10746738
Claudin-1 peptide reagents and methods
granted -
US 10744154
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
granted -
US 10744103
Methods and compositions for treating conditions associated with an abnormal inflammatory responses
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.